In June 2020, BSV formed a strategic alliance with LaVoieHealthScience in order to enhance BSV's capabilities to communicate value. <read more here>                     In May 2020, BSV entered into a strategic alliance with FCF Fox Corporate Finance to support funding activities. <read more here>                    
 
                           COVID-19 Portal               Home      About      Team      Clients      Publications      Downloads      News      Career      Contact

Testimonials
  With the dedicated support, and particularly the experienced, constructive work of Bioscience Valuation, we accomplished meaningful results that provide important new knowledge enabling our next steps in diabetes research. We sincerely thank the entire Bioscience Valuation team for their valuable and straightforward collaboration in the past year, and look forward to the next opportunity of working with them again.

Prof. Dr. Thomas Danne, Director, and Dr. Bärbel Aschemeier, Clinical Research, AUF DER BULT Hospital for Children and Adolescents

 

Core Services
  Financial Valuation
  Commercial Assessment &
Pharmacoeconomics

  R&D Risk Analysis &
Productivity Increase

  Portfolio Management
  Investment Decisions
  Partnering / Licensing
  Corporate Finance / M&A

Special Expertise
  Economic Modeling
of Healthcare Systems

  Assessing the Economics
of Personalized Medicine

Comprehensive Support
  Corporate Partnership Program

Products
  Market Model
  R&D Risk Model
  Valuation Model

Special Expertise - Economic Modeling of
Healthcare Systems


Healthcare Systems Modeling supports decision and policy makers in predicting the impact of new regulations or healthcare policies on their company's revenues. One example are new regulations to contain healthcare spending. Also, companies may design new products that are expected to have an impact on healthcare systems. Bioscience Valuation can assess the effects in a quantitative way. When modeling healthcare systems, Bioscience Valuation
  • collects all available information, either published and / or through interviews with relevant stakeholders,
  • a quantitative model is created and the available infomation is used to validate the model,
  • the impact of new regulations or new products is assessed and the results are analyzed,
  • a comprehensive report is generated that demonstrates the impact of the new policies or products,
  • Bioscience Valuation assists its clients in the communication of the healthcare modeling results.


Case:
A leading US-based healthcare service provider developed a new system that should produce considerable savings to payers. A Patients' Compensation System shall be introduced that could significantly reduce the practice of defensive medicine. Bioscience Valuation quantified the savings to Medicare, Medicaid and private insurance companies.

The new system is being implemented in Georgia and Florida. Bioscience Valuation's work is cited in the Wall Street Journal (WSJ March 20, 2013).





This website uses cookies to ensure you get the best experience on our website.
Privacy Policy